Phase III trials
Clinical Trials Watch
This section contains information about clinical trials that are:
- Currently recruiting participants
- Conducted at least in one European country
- In phase III (in these trials the drug / treatment is tested in large groups of people, involving from several hundred to several thousand participants. These trials are conducted to provide stronger evidence of the effectiveness and safety of the new drug / treatment.)
How many Phase III trials are reported in the CTW?
The CTW reports currently 10 ongoing Phase III clinical trials recruiting participants in Europe. These trials are listened in the table below:
| Study | Study sponsor | Name of the drug | Condition |
| GENERATION S1 | Novartis | CAD106 and CNP520 | Risk of developing Alzheimer's dementia |
| GENERATION S2 | Novartis | CNP520 | Risk of developing Alzheimer's dementia |
| GRADUATE 1 & GRADUATE 2 | Hoffmann- La Roche | Gantenerumab | Prodromal to mild Alzheimer’s disease |
| HARMONY | ACADIA Pharmaceuticals Inc. | Pimavanserin | People with dementia-related psychosis |
| LUCIDITY | TauRx Therapeutics Ltd | TRx0237 | Mild Alzheimer's disease |
| MissionAD1 & MissionAD2 | Eisai | Elenbecestat | Early Alzheimer's disease |
| SYMBAD | University of Sussex | Mirtazapine and Carbamazepine | Alzheimer's disease and agitated behaviours |
| 17-AVP-786-305 | Avanir Pharmaceuticals | AVP-786 | Agitation in people with dementia of the Alzheimer's type |
Last Updated: Wednesday 05 June 2019
